Scott Lundgren, DO
Advanced Heart Failure and Transplant Cardiology · Omaha, NENPI 1487092086
Payments from drug & device makers
Across 549 payments — averaging $419.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$160K
- Bayer$53K
- Medtronic$11K
- Cvrx, Inc.$2K
- Abiomed$1K
- One Lambda, Inc.$1K
- plus $1K from 11 others
What the payments were for
- Consulting fees$112,02162%
- Speaking & faculty fees$3,5192%
- Grants$8,7505%
- Travel & lodging$39,12022%
- Food & beverage$15,8189%
- Education$1830%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 422 | $160,484 |
| Bayer | 14 | $52,658 |
| Medtronic | 16 | $11,314 |
| Cvrx, Inc. | 16 | $1,981 |
| Abiomed | 26 | $1,136 |
| One Lambda, Inc. | 2 | $1,037 |
| Novartis | 26 | $397 |
| Paragonix Technologies, Inc. | 1 | $297 |
| Impulse Dynamics (USA) Inc. | 12 | $249 |
| United Therapeutics Corporation | 1 | $145 |
| Boston Scientific | 5 | $119 |
| Vifor Pharma, Inc. | 1 | $119 |
| Pfizer | 3 | $42 |
| Heartflow, Inc. | 1 | $20 |
| Akcea Therapeutics, Inc. | 1 | $20 |
| Edwards Lifesciences | 1 | $18 |
| AstraZeneca | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CARDIOMEMS$125,799
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$21,546
- HeartWare HVAD$10,250
- CardioMEMS HF System$3,866
- HeartMate 3 Left Ventricular Assist Device$2,375
- Kerendia$1,841
- Barostim Neo System$1,646
- HeartMate 3 Left Ventricular Dev$799
- TYVASO$145
- REMODULIN$145
- Adempas$125
- Veltassa$119
- Arctic Front$105
How this compares
Too few advanced heart failure and transplant cardiology providers in Nebraskato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 180 | $156,843 |
| EntrestoSacubitril/Valsartan | 131 | $141,780 |
| JardianceEmpagliflozin | 103 | $107,694 |
| EliquisApixaban | 64 | $73,236 |
| XareltoRivaroxaban | 14 | $12,117 |
| MounjaroTirzepatide | 11 | $11,569 |
| Sildenafil Citrate | 33 | $11,440 |
| Mycophenolic AcidMycophenolate Sodium | 12 | $9,879 |
| CorlanorIvabradine Hcl | 13 | $9,779 |
| Tacrolimus | 27 | $4,446 |
| Torsemide | 108 | $4,235 |
| Metoprolol Succinate | 186 | $2,968 |
| Potassium Chloride | 33 | $2,002 |
| Eplerenone | 24 | $1,977 |
| Spironolactone | 244 | $1,608 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $18 | $156,843180 claims |
| NovartisEntresto | $397 | $141,780131 claims |
| PfizerEliquis | $42 | $73,23664 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few advanced heart failure and transplant cardiology providers in Nebraskaon file to place this against a meaningful peer group, so we don't.
Other advanced heart failure and transplant cardiology in Omaha
- Douglas StollerOmaha$645K
- Selma MohammedOmaha$139K
- Brian LowesOmaha$24K
- Jason ColeOmaha$155
- Mathue BakerLincoln$639K
- Arif AlbulushiBellevue$51K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.